LPIN3

Across TCGA pan-cancer cohorts, LPIN3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LPIN3 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LPIN3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LPIN3 expression acts as an unfavorable survival marker.

LIHC, KICH, and LUAD are the cancer types where LPIN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.051	0.738	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	DFS	Median	All	0.211	0.666	.004	12	view →
COAD	OS	Median	All	0.149	0.676	.002	10	view →
SKCM	DFS	Median	II,III,IV	0.167	0.712	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LPIN3–LIHC (OS)

Open the LIHC breakdown →